Embedded Files
Mariwan K. Rasheed, Ban M. Rashid, Mohammed O. Mohammed, Najmaddin S.H. Khoshnaw, Nawshirwan G. Rashid, Shwan Ali Tawfiq, Dana O. Karim, Banaz M. Safar, Nihayat A. Ahmad, Beston F. Nore
Department of Anatomy, Department of Medicine, and Department of Biochemistry, School of Medicine, Faculty of Medical Sciences, University of Sulaimani, Kurdistan Region - Iraq,
Department of Clinical Biochemistry, School of Pharmacy, Faculty of Medical Sciences, University of Sulaimani, Sulaimani, Kurdistan Region - Iraq,
Hiwa Hematology-Oncology Center, Department of Hematology, Sulaimani, Kurdistan Region - Iraq
Kurdistan Institution for Strategic Studies and Scientific Research, Department of Health, Sulaimani, Kurdistan Region - Iraq
DOI: https://doi.org/10.17656/jzs.10562
Abstract
Detection and diagnosis of the myeloproliferative neoplasms (MPNs) are difficult to predict without screening for genetic causes, includingpolycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic myeloid leukemia (CML). A novel mutation in the Janus kinase 2 (JAK2) gene has been described as a genetic marker prime for all four-types of MPNs.The specific c.1851G>T (p.V617F) mutation leads to constitutively activetyrosine kinase activity of JAK2, inducing downstream JAK/STAT pathways of cytokine signaling. The existence of the JAK2(c.1851G>T; p.V617F) mutation has a clinical importance in diagnosis of MPNs. In this study, amplification refractory mutation system (ARMS) assay for a specific mutation detection was utilized, which is an Allele Specific Oligonucleotide (ASO) based multiplex PCR method. Genomic DNA samples were isolated from total blood samples from suspected MPN patients, who visited Hiwa hospital (the main teaching hospital for cancer in Sulaimani city). The aim of this study was to screen for JAK2 mutation c.1851G>T (p.V617F) on a group of suspected patients for MPNs (100 patients). The result shows that 65% of patients had indeed c.1851G>T mutation and the rest 35% of patients were normal for the mutation. In this study, we have shown the ARMS assay method to be quick, simple, cheap, reliable, and gives sufficient sensitivity for positive detection compatible forclinical diagnostic purposes. Therefore, the assay can be used for early diagnosis of MPNsin diagnostic laboratories with limited resources, such as in our health care system in our locality.
Key Words: JAK2 mutation; Polycythemia vera; Essential thrombocythemia; Primary myelofibrosis; Chronic myeloid leukemia; Splenomegaly.
Reference
[1] Baxter, E. J., Scott L. M., Campbell P. J., East C., Fourouclas N., Swanton S., Vassiliou G. S., Bench A. J., Boyd E. M., Curtin N., Scott M. A., Erber W. N. & Green, A. R. "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", Lancet, Vol. 365, pp 1054-1061. (2005).
[2] Ha J. S., Kim Y. K., Jung S. I., Jung H. R. & Chung I. S. "Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms". Ann Lab Med, Vol. 32, pp 385-391. (2012).
[3] Ismael O., Shimada A., Hama A., Sakaguchi H., Doisaki S., Muramatsu H., Yoshida N., Ito M., Takahashi Y., Akita N., Sunami S., Ohtsuka Y., Asada Y., Fujisaki H. & Kojima S. "Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children". Pediatr Blood Cancer, Vol. 59, pp 530-535. (2012).
[4] James C. "The JAK2 V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases" Hematology Am Soc Hematol Educ Program, pp 69-75. (2008).
[5] James C., Ugo V., Le Couedic J. P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J. L., Constantinescu S. N., Casdevall N. & Valinchenker W. "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera". Nature,Vol. 434, pp 1144-1148. (2005).
[6] Kim H. R., Choi H. J., Kim Y. K., Kim H. J., Shin J. H., Suh S. P., Ryang D. W. & Shin M. G. "Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms". PLoS One, Vol. 8, e52518. (2013).
[7] Kilpivaara O. & Levine R. L. "JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science". Leukemia, Vol. 22, pp 1813-1817. (2008).
[8] Koskal V., Etlik O., Arican-Baris S. T. & Baris I. "A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation". Genet Test, Vol. 11, pp 463-466. (2007).
[9] Lafave L. M. & Levine R. L. "JAK2 the future: therapeutic strategies for JAK-dependent malignancies". Trends Pharmacol Sci. Vol. 33, pp 574-582. (2012).
[10] Levine R. L., Wadleigh M., Cools J., Ebert B. L., Wernig G., Huntly B. J., Boggon T. J., Wlodarska I., Clark J. J., Moore S., Adelsperger J., Koo S., Lee J. C., Gabriel S., Mercher T., D'andrea A., Frohling, S., Dohner K., Marynen P., Vandenberghe P., Mesa R. A., Tefeferi A., Griffin J. D., Eck M. J., Sellers W. R., Meyerson M., Golub T. R., Lee S. J. & Gilliland D. G. "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis". Cancer Cell, Vol. 7, pp 387-397. (2005).
[11] Lieu C. H., Wu H. S., Hon Y. C., Tsai W. H., Yang C. F., Wang C. C., Lin Y. C., Shih C. H. & Hsu H. C. "Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders". Intern Med J, Vol. 38, pp 422-426. (2008).
[12] Poodt J., Fijnheer R., Walsh I. B. & Hermans M. H. "A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood". Hematol Oncol, Vol. 24, pp 227-233. (2006).
[13] Sattler M., Walw C., Crowley B. J., Lengfelder E., Janne P. A., Rogers A. M., Kuang Y., Distel R. J., Reiter A. & Griffin J. D. "A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples". Blood, Vol. 107, pp 1237-1238. (2006).
[14] Tefferi A. & Gilliland D. G. "The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis". Mayo Clin Proc, Vol. 80, pp 947-958. (2005).
[15] Vakil E. & Tefferi A. "BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment". Clin Lymphoma Myeloma Leuk, Vol. 11 Suppl1, S37-45. (2011).
Page updated
Report abuse